Beijing E-Town International Investment & Development Co., Ltd.
亦庄国投
Beijing E-Town International Investment & Development (亦庄国投) shows up in elsewhere's corpus as a Beijing state-backed investment vehicle active as a follow-on and lead investor across hard-tech and biotech rounds, rather than as a profiled subject in its own right. Its visible activity includes co-investing in Oricell Therapeutics' $70M Series C first tranche (January 2026) and $110M Pre-IPO round (April 2026), alongside Qiming Venture Partners and Beijing's pharmaceutical and health industry fund ; backing gene-sequencing company Sainuo Bio across multiple rounds since 2023 ; joining humanoid-robotics startup AheadForm's A1 round ; and leading, through an industry-upgrading fund it manages, OakDeer Robotics' 300 million yuan round reported in April 2026, per Source Code Capital . The corpus doesn't carry a standalone profile of the firm — its founding, AUM, and structure aren't covered — but the deal pattern points to a government-affiliated platform deploying into Beijing's priority sectors: biotech, robotics, and advanced manufacturing.
AI-generated — may contain errors, please verify.
Coverage
OriCell Therapeutics Announces $110 Million Pre-IPO Round, Co-Led by Qiming Venture Partners
Global leader in innovative tumor immunotherapy
Shouxing Technology Secures Hundreds of Millions of Yuan in New A1 Round; Humanoid Robot Makes Cover Debut in *Science Robotics*
Humanoid emotional-interaction robotics company AheadForm has announced the completion of a Series A1 round totaling several hundred million RMB.
Source Code Snapshot | "Oak Deer Robotics" Closes 300 Million Yuan Funding Round, Source Code Capital Sole Angel Investor
AI Cooking Robots Enter New Phase of Scaled Deployment
Oricell Therapeutics Closes First Tranche of $70M Series C to Accelerate Global Development of Solid Tumor CAR-T Therapies
A global leader in innovative tumor immunotherapy
MaHui Spotlight | Booster Robotics, a MaHui member humanoid robotics company, closes new funding round with existing investor Source Code Capital increasing its stake
Continue strengthening mass-production and delivery capabilities
MaHui | MaHui Member Sainuo Biotech Closes New Funding Round Exceeding 100 Million Yuan, Continues Focus on Core Gene Sequencing Technology
Source Code Capital | "Sainuo Biology" Completes Hundreds of Millions of RMB in Series C+ Funding, Led by Source Code Capital
With this round of capital, Sainuo Bio will stay true to its founding mission, leverage its team's proprietary R&D strengths, actively refine its product portfolio, and vigorously advance its commercialization efforts.
